Merck is a new year outlier with its diabetes drug

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Happy New Year, biotech friends! We’re back with news, including Merck’s decision to cut the price of its diabetes drug Januvia by 42% and Neumora’s readout on its  experimental depression drug. Also, is the best way to “save the FDA” to break it apart?

Read the rest…